Literature DB >> 18163491

Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis.

M van Oosterhout1, I Bajema, E W N Levarht, R E M Toes, T W J Huizinga, J M van Laar.   

Abstract

OBJECTIVE: To compare synovial tissue infiltrates from patients with anti-cyclic citrullinated peptide (anti-CCP)-positive rheumatoid arthritis (RA) with those from patients with anti-CCP-negative RA.
METHODS: Synovial tissue samples were obtained arthroscopically from the inflamed knee joints of 57 patients with RA (34 of whom were anti-CCP positive) and examined for several histologic features along with immunohistologic expression of cell markers. Joint damage was assessed using the Kellgren/Lawrence (K/L) scale (range 0-4) on standard anteroposterior radiographs. In 31 patients (18 of whom were anti-CCP positive), synovial tissue was available from an earlier time point, allowing analysis of temporal changes.
RESULTS: Synovial tissue from anti-CCP-positive patients was characterized by a higher mean number of infiltrating lymphocytes (61.6 versus 31.4/high-power field [hpf] [400x]; P=0.01), less extensive fibrosis (mean score of 1.2 versus 2.0; P=0.04), and a thinner synovial lining layer (mean score of 2.1 versus 3.3; P=0.002) compared with synovial tissue from anti-CCP-negative patients. Anti-CCP-positive patients expressed more CD3, CD8, CD45RO, and CXCL12. More anti-CCP-positive patients had a K/L score >1 compared with anti-CCP-negative patients. The difference in the mean lymphocyte counts was already present a mean of 3.8 years before the index biopsy (76.7 lymphocytes/hpf and 26.7 lymphocytes/hpf in anti-CCP-positive patients and anti-CCP-negative patients, respectively; P=0.008) and was independent of disease duration and K/L score.
CONCLUSION: Synovitis in patients with anti-CCP-positive RA differs from that in patients with anti-CCP- negative RA, notably with respect to infiltrating lymphocytes, and is associated with a higher rate of local joint destruction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18163491     DOI: 10.1002/art.23148

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

1.  Evidence for interaction between 5-hydroxytryptamine (serotonin) receptor 2A and MHC type II molecules in the development of rheumatoid arthritis.

Authors:  Maria Seddighzadeh; Marina Korotkova; Henrik Källberg; Bo Ding; Nina Daha; Fina A S Kurreeman; Rene E M Toes; Tom W Huizinga; Anca I Catrina; Lars Alfredsson; Lars Klareskog; Leonid Padyukov
Journal:  Eur J Hum Genet       Date:  2010-02-24       Impact factor: 4.246

2.  Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: clues to disease pathogenesis.

Authors:  Mary K Crow
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 3.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 4.  Anti-CCP antibodies: the past, the present and the future.

Authors:  Walther J van Venrooij; Joyce J B C van Beers; Ger J M Pruijn
Journal:  Nat Rev Rheumatol       Date:  2011-06-07       Impact factor: 20.543

Review 5.  The influence of ACPA status and characteristics on the course of RA.

Authors:  Annemiek Willemze; Leendert A Trouw; René E M Toes; Tom W J Huizinga
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 6.  The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis.

Authors:  Ger Jm Pruijn; Allan Wiik; Walther J van Venrooij
Journal:  Arthritis Res Ther       Date:  2010-02-15       Impact factor: 5.156

7.  Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study.

Authors:  Hideki Nakamura; Atsushi Kawakami; Tomayoshi Hayashi; Naoki Iwamoto; Akitomo Okada; Mami Tamai; Satoshi Yamasaki; Hiroaki Ida; Katsumi Eguchi
Journal:  BMC Musculoskelet Disord       Date:  2010-07-01       Impact factor: 2.362

8.  The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis.

Authors:  Mohammed Z Cader; Andrew D Filer; Christopher D Buckley; Karim Raza
Journal:  BMC Musculoskelet Disord       Date:  2010-08-23       Impact factor: 2.362

Review 9.  Current concepts in the pathogenesis of early rheumatoid arthritis.

Authors:  Arthur G Pratt; John D Isaacs; Derek L Mattey
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-02       Impact factor: 4.098

10.  Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.

Authors:  Burkhard Möller; Daniel Aeberli; Stefan Eggli; Martin Fuhrer; Istvan Vajtai; Esther Vögelin; Hans-Rudolf Ziswiler; Clemens A Dahinden; Peter M Villiger
Journal:  Arthritis Res Ther       Date:  2009-05-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.